Cargando…
Nanotechnological Advances for Nose to Brain Delivery of Therapeutics to Improve the Parkinson Therapy
Blood-Brain Barrier (BBB) acts as a highly impermeable barrier, presenting an impediment to the crossing of most classical drugs targeted for neurodegenerative diseases including Parkinson's disease (PD). About the nature of drugs and other potential molecules, they impose unavoidable dose-rest...
Autores principales: | Khatri, Dharmendra K., Preeti, Kumari, Tonape, Shivraj, Bhattacharjee, Sheoshree, Patel, Monica, Shah, Saurabh, Singh, Pankaj K., Srivastava, Saurabh, Gugulothu, Dalapathi, Vora, Lalitkumar, Singh, Shashi B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Bentham Science Publishers
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10207920/ https://www.ncbi.nlm.nih.gov/pubmed/35524671 http://dx.doi.org/10.2174/1570159X20666220507022701 |
Ejemplares similares
-
CRISPR/Cas9 assisted stem cell therapy in Parkinson's disease
por: Pinjala, Poojitha, et al.
Publicado: (2023) -
Microtubule acetylation dyshomeostasis in Parkinson’s disease
por: Naren, Padmashri, et al.
Publicado: (2023) -
Understanding the Involvement of microRNAs in Mitochondrial Dysfunction and Their Role as Potential Biomarkers and Therapeutic Targets in Parkinson’s Disease
por: Tryphena, Kamatham Pushpa, et al.
Publicado: (2023) -
Meloxicam in Combating Clinical Mastitis: Nanotechnology-Driven Hope and Opportunities
por: Jyothi, Vaskuri G. S. Satya Sainaga, et al.
Publicado: (2022) -
Neuroprotective Effect of Phloretin in Rotenone-Induced Mice Model of Parkinson’s Disease: Modulating mTOR-NRF2-p62 Mediated Autophagy-Oxidative Stress Crosstalk
por: Shirgadwar, Shubhendu M., et al.
Publicado: (2023)